Literature DB >> 24962661

Impaired estimated glomerular filtration rate is a significant predictor for non-muscle-invasive bladder cancer recurrence and progression--introducing a novel prognostic model for bladder cancer recurrence.

Steffen Rausch1, Jörg Hennenlotter2, Tilman Todenhöfer2, Stefan Aufderklamm2, Christian Schwentner2, Karl-Dietrich Sievert2, Arnulf Stenzl2, Georgios Gakis2.   

Abstract

PURPOSE: To evaluate the influence of preoperative patient-associated parameters and comorbidities, with special focus on preoperative renal function on non-muscle-invasive bladder carcinoma (NMIBC) recurrence and progression. PATIENTS AND METHODS: Medical records of 192 patients with first diagnosis of NMIBC from 1996 to 2006 treated at our department were reviewed for tumor stage and grade, comorbidities, and putative preoperative risk factors (diabetes mellitus, smoking habits, C-reactive protein levels, estimated glomerular filtration rate [eGFR] by chronic kidney disease-epidemiology collaboration formula, patient age, and sex).
RESULTS: Median follow-up was 80 months. Tumor recurrence was observed in 104 patients (54%); progression to higher pT category or grade was found in 43 patients (22%). Overall, 20 (10%) patients had progression to category pT2, with a median time to progression of 11 months (95% CI: 3.16-55.77). Overall, median time to recurrence was 11.91 months (8.00-14.94), while median time to progression to higher category/grade was 15 months (8.60-36.95). Cancer-specific death was recorded for 12 patients (6%). Univariate analysis revealed category, grade, and eGFR < 60 ml/min as significant predictive determinants for recurrence, overall progression, and progression to pT2-category disease. Based on the results of multivariate analysis, a risk factor model was created to classify patients with high and low risk of recurrence.
CONCLUSIONS: eGFR is a significant predictive variable of NMIBC recurrence and progression. Integrating eGFR into NMIBC risk calculation helped to discriminate individuals with high and low risk of cancer recurrence. Confirmatory studies and external validation are needed to corroborate these findings. Furthermore, the role of tumor multifocality and size should be analyzed for the proposed prediction model.
Copyright © 2014 Elsevier Inc. All rights reserved.

Entities:  

Keywords:  Bladder cancer; Chronic kidney disease; Comorbidities; Creatinine; Non–muscle invasive; Prognosis; eGFR

Mesh:

Substances:

Year:  2014        PMID: 24962661     DOI: 10.1016/j.urolonc.2014.05.009

Source DB:  PubMed          Journal:  Urol Oncol        ISSN: 1078-1439            Impact factor:   3.498


  14 in total

1.  Preoperative chronic kidney disease is predictive of oncological outcome of radical cystectomy for bladder cancer.

Authors:  Akihiko Matsumoto; Tohru Nakagawa; Atsushi Kanatani; Masaomi Ikeda; Taketo Kawai; Jimpei Miyakawa; Satoru Taguchi; Akihiro Naito; Masafumi Otsuka; Yasukazu Nakanishi; Motofumi Suzuki; Fumitaka Koga; Yasushi Nagase; Yasushi Kondo; Toshikazu Okaneya; Yoshinori Tanaka; Hideyo Miyazaki; Tetsuya Fujimura; Hiroshi Fukuhara; Haruki Kume; Yasuhiko Igawa; Yukio Homma
Journal:  World J Urol       Date:  2017-11-28       Impact factor: 4.226

2.  The association of preoperative reduced glomerular filtration rate with higher staging and histology grades in patients with urinary tract cancers.

Authors:  Vedran Premuzic; Tvrtko Hudolin; Luka Penezic; Ines Golubic; Marija Gamulin; Bojan Jelakovic; Zeljko Kastelan
Journal:  Int Urol Nephrol       Date:  2019-06-24       Impact factor: 2.370

3.  Chronic kidney disease as an important risk factor for tumor recurrences, progression and overall survival in primary non-muscle-invasive bladder cancer.

Authors:  Chia-En Li; Chia-Shen Chien; Yao-Chi Chuang; Ye-In Chang; Hsiu-Pei Tang; Chih-Hsiung Kang
Journal:  Int Urol Nephrol       Date:  2016-03-19       Impact factor: 2.370

4.  Prognostic Value of Pre-operative Renal Insufficiency in Urothelial Carcinoma: A Systematic Review and Meta-Analysis.

Authors:  Jian Cao; Xiaokun Zhao; Zhaohui Zhong; Lei Zhang; Xuan Zhu; Ran Xu
Journal:  Sci Rep       Date:  2016-10-11       Impact factor: 4.379

5.  Prognostic value of impaired estimated glomerular filtration rate in intravesical BCG-treated non-muscle-invasive bladder cancer patients.

Authors:  Bum Sik Tae; Jung Kwon Kim; Minyong Kang; Chang Wook Jeong; Cheol Kwak; Hyeon Hoe Kim; Ja Hyeon Ku
Journal:  Sci Rep       Date:  2017-05-03       Impact factor: 4.379

6.  High-soluble CGA levels are associated with poor survival in bladder cancer.

Authors:  T Szarvas; B Jardin-Watelet; N Bourgoin; M J Hoffmann; P Nyirády; C Oláh; T Széll; A Csizmarik; B Hadaschik; H Reis
Journal:  Endocr Connect       Date:  2019-05-01       Impact factor: 3.335

7.  Prognostic value of serum creatine level in patients with vulvar cancer.

Authors:  Richard Schwameis; Magdalena Postl; Christine Bekos; Lukas Hefler; Alexander Reinthaller; Veronika Seebacher; Christoph Grimm; Stephan Polterauer; Samir Helmy-Bader
Journal:  Sci Rep       Date:  2019-07-31       Impact factor: 4.379

8.  Long noncoding RNA LINC01296 promotes cancer-cell proliferation and metastasis in urothelial carcinoma of the bladder.

Authors:  Xiaofei Wang; Lei Wang; Yanbing Gong; Zhenzhen Liu; Yingchao Qin; Jia Chen; Ningcheng Li
Journal:  Onco Targets Ther       Date:  2018-12-19       Impact factor: 4.147

9.  Lifestyle and Non-muscle Invasive Bladder Cancer Recurrence, Progression, and Mortality: Available Research and Future Directions.

Authors:  Kyle B Zuniga; Rebecca E Graff; David B Feiger; Maxwell V Meng; Sima P Porten; Stacey A Kenfield
Journal:  Bladder Cancer       Date:  2020-03-28

10.  Areca Nut Chewing and an Impaired Estimated Glomerular Filtration Rate as Significant Risk Factors for Non-Muscle-Invasive Bladder Cancer Recurrence.

Authors:  Jian Cao; Ran Xu; Xiaokun Zhao; Zhaohui Zhong; Lei Zhang; Xuan Zhu; Shuiqing Wu; Kai Ai
Journal:  Sci Rep       Date:  2016-07-07       Impact factor: 4.379

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.